DocuSign Q1 Loss Narrows

DocuSign, Inc. (DOCU), Thursday reported first-quarter net loss of $8.4 million or $0.04 per share, narrower than last year's loss of $47.8 million or $0.26 per share last year.

Adjusted earnings for the quarter were $0.44 per share, up from $0.12 per share last year.

Revenue for the quarter increased 58% to $469.1 million from $297.0 million last year. Subscription revenue gained 61% to $451.9 million, while Professional services and other revenue rose 7% to $17.1 million.

Analysts polled by Thomson Reuters expected earnings of $0.28 per share on revenues of $437.81 million.

Billings were $527.4 million, an increase of 54% year-over-year. Gross margin was 78% compared to 75% in the same period last year.

Looking forward to the second quarter, the computer expects revenues of $479 million to $485 million. Analysts currently estimate revenues of $473.68 million.

For the full year 2022, the company expects revenues of $2.03 billion to $2.04 billion. Analysts currently estimate revenues of $1.98 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
Follow RTT